The restoration of NIS expression mediated by deacetylase inhibitors [19], as already shown in breast cancer cells (MDA 157 and MDA 468) [20,21], could represent a valuable advancement in the therapy of thyroid cancer. Here, SLC5A5 is linked to thyroid gland carcinoma.